tbuckley/cabot-search huggingface dataset:
A case of portal hypertension by presumed as plexiform neurofibroma at the hepatic hilum
Authors: Kyung Han Lee, Sun Hong Yoo, Gi Tark Noh, Won Suk Heo, Byung Seong Ko, Jung Ah Chio, Hyo Jin Cho, Jin Young Choi, Hee Jun Kim, Won Sohn, Sang Jong Park, Young Min Park
Journal: Clinical and Molecular Hepatology (2016)

Neurofibromas can occur anywhere in the body, but they usually involve the head, neck, pelvis, and extremities. Abdominal visceral involvement is rare, and intrahepatic involvement is even less common. We describe a patient who suffered from plexiform neurofibromatosis with liver involvement. A 49-year-old man, who had previously been diagnosed with neurofibromatosis, underwent esophagogastroduodenoscopy and abdominal ultrasonography for screening purposes. Esophagogastroduodenoscopy showed grade 2 esophageal varices and abdominal ultrasonography showed conglomerated nodules with echogenic appearances in the perihepatic space. Magnetic resonance imaging showed presumed plexiform neurofibroma involving the lesser sac and hepatic hilum and encasing the common hepatic artery celiac trunk and superior mesenteric artery left portal triad. We report an unusual case of portal hypertension attributed to the compressive narrowing of the portal vein by presumed as plexiform neurofibroma at the lesser sac and hepatic hilum. Keywords: Plexiform neurofibroma; Portal hypertension; Esophageal varix
Symposium Presentations
Authors: Michael E. Mendelsohn, C. William Balke, Robert O. Bonow, Valentin Fuster, Augustus O. Grant, Daniel B. Mark, Eric D. Peterson, Elliott M. Antman, Harlan M. Krumholz, Robert S. Balaban, Eric N. Prystowsky, James J. Ferguson, Thabet O. Al-Sheikh, Bradford C. Berk, Stephen F. Vatner, Douglas P. Zipes, David R. Holmes, Christine E. Seidman, Elizabeth G. Nabel, William A. Zoghbi
Journal: Journal of the American College of Cardiology (2005)
Breathtaking Journey
Authors: David K. Rhee, Roger P. Clark, Ralph J. Blair, Joel T. Katz, Joseph Loscalzo
Journal: New England Journal of Medicine (2012)

A 48-year-old man came to the emergency department in early August with a 3-day history of influenza-like symptoms and profound dyspnea on exertion, which had started 3 days after his return to Boston from a vacation in California.
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
Authors: Bjoern Chapuy, Hongwei Cheng, Akira Watahiki, Matthew D. Ducar, Yuxiang Tan, Linfeng Chen, Margaretha G. M. Roemer, Jing Ouyang, Amanda L. Christie, Liye Zhang, Daniel Gusenleitner, Ryan P. Abo, Pedro Farinha, Frederike von Bonin, Aaron R. Thorner, Heather H. Sun, Randy D. Gascoyne, Geraldine S. Pinkus, Paul van Hummelen, Gerald G. Wulf, Jon C. Aster, David M. Weinstock, Stefano Monti, Scott J. Rodig, Yuzhuo Wang, Margaret A. Shipp
Journal: Blood (2016)
Prognostic and predictive role of 18F-choline (c) positron emission tomography (PET) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide (ENZ) after docetaxel (DOC) failure
Authors: A. Veccia, F. Maines, O. Caffo, C. Trentin, D. Donner, F. Chierichetti, I. Sperduti, E. Bria, E. Galligioni
Journal: Annals of Oncology (2015)
Abstract P2-03-08: miR-621 suppresses the metastatic cascade in breast cancer patients
Authors: J Xue, Y Chi, J Chen, B Yang, J Wu
Journal: Cancer Research (2016)

Abstract Purpose: In previous study, we had shown that miR-621 could sensitize breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. In this study, we aimed to define miR-621 prognosis value in breast cancer patients, and to explore the potential molecular mechanisms. Experimental Design: 70 patients with stages II and III breast cancer were included as validation set. The correlation between miR-621 expression level and prognosis in breast cancer patients was confirmed. In parallel, in vitro and in vivo analyses were carried out to determine the potential mechanisms of miRNA-dependent prognosis. Results: We validated that lower than higher miR-621 expression level was markedly associated with poor metastasis-free survival in breast cancer patients(P=0.03). In breast cancer cell lines, ectopic overexpression of miR-621 inhibited proliferation, migration, invasion, and metastasis both in vitro and in vivo. The potential miR-621-target genes were determined by TargetScan and miRNA CLIP-seq database. Among those, PAK7 was verified as one of the direct targets of miR-621 in breast cancer cells, whose expression level positively associated with recurrence and metastasis in breast cancer patients. The molecular mechanisms by which miR-621/PAK7 axis regulates recurrence and metastasis may involve regulation of epithelial-mesenchymal transition (EMT) in breast cancer cells. Conclusions: Our study revealed a strong correlation between miR-621 expression and metastasis in breast cancers. High level of miR-621 was negatively associated with poor metastasis-free survival. The increased metastasis-free survival may be mediated by down-regulation of PAK7 gene, which leads to reduced EMT in breast cancer cells. Therefore, miR-621 may represent a therapeutic target for early metastasis breast cancer. Citation Format: Xue J, Chi Y, Chen J, Yang B, Wu J. miR-621 suppresses the metastatic cascade in breast cancer patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-03-08.
Effect of length of inpatient treatment for chronic schizophrenia
Authors: C L Caton
Journal: American Journal of Psychiatry (1982)

Brief hospitalization policies have accompanied the deinstitutionalization movement, yet length of inpatient stay in facilities under state and local administration remains quite varied. A 1-year study of 119 chronic schizophrenic patients hospitalization in New York City between 1977 and 1979 revealed that length of inpatient stay bore no relationship to subsequent hospitalization, treatment compliance, or clinical or social functioning in the community. Rather, a patient's postdischarge experiences with treatment and significant others in the community were critical in determining subsequent use of inpatient services. This finding points to the need for wider application of briefer hospitalization policies for the dischargeable chronic schizophrenic patient.
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Authors: Sumita Trivedi, Raghvendra M. Srivastava, Fernando Concha-Benavente, Soldano Ferrone, Tatiana M. Garcia-Bates, Jing Li, Robert L. Ferris
Journal: Clinical Cancer Research (2016)

Abstract Purpose: EGF receptor (EGFR) is highly overexpressed on several cancers and two targeted anti-EGFR antibodies which differ by isotype are FDA-approved for clinical use. Cetuximab (IgG1 isotype) inhibits downstream signaling of EGFR and activates antitumor, cellular immune mechanisms. As panitumumab (IgG2 isotype) may inhibit downstream EGFR signaling similar to cetuximab, it might also induce adaptive immunity. Experimental Design: We measured in vitro activation of cellular components of the innate and adaptive immune systems. We also studied the in vivo activation of components of the adaptive immune system in patient specimens from two recent clinical trials using cetuximab or panitumumab. Results: Both monoclonal antibodies (mAb) primarily activate natural killer (NK) cells, although cetuximab is significantly more potent than panitumumab. Cetuximab-activated neutrophils mediate antibody-dependent cellular cytotoxicity (ADCC) against head and neck squamous cell carcinomas (HNSCC) tumor cells, and interestingly, this effect was FcγRIIa- and FcγRIIIa genotype–dependent. Panitumumab may activate monocytes through CD32 (FcγRIIa); however, monocytes activated by either mAb are not able to mediate ADCC. Cetuximab enhanced dendritic cell (DC) maturation to a greater extent than panitumumab, which was associated with improved tumor antigen cross-presentation by cetuximab compared with panitumumab. This correlated with increased EGFR-specific cytotoxic CD8+ T cells in patients treated with cetuximab compared with those treated with panitumumab. Conclusions: Although panitumumab effectively inhibits EGFR signaling to a similar extent as cetuximab, it is less effective at triggering antitumor, cellular immune mechanisms which may be crucial for effective therapy of HNSCC. Clin Cancer Res; 22(21); 5229–37. ©2016 AACR.
HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344
Authors: D. F. Hayes, A. Thor, L. Dressler, D. Weaver, G. Broadwater, L. Goldstein, S. Martino, J. Ingle, I. C. Henderson, D. Berry
Journal: Journal of Clinical Oncology (2006)

510 Background: CALGB 9344 showed 4 cycles of paclitaxel (T) after 4 cycles of doxorubicin/cyclophosphamide (AC) improved disease-free (DFS) and overall survival (OS) compared to 4 cycles of AC. Higher dose of A had no benefit (Henderson JCO ’03). Prior studies suggest HER2 is associated with benefit from standard vs low dose of C&amp;A (Dressler JCO ’05). We hypothesized that HER2 might predict benefit from higher dose of A or from T, and that HER2 might refine the observed negative interaction of T with estrogen receptor (ER). Methods: 3121 node + women in CALGB 9344 received 4 q3wk cycles of AC (A: 60, 75, or 90 mg/m 2 ) and then 4 cycles of T (175 mg/m 2 q3wk) or no T. Blocks were collected from ∼2800 subjects. 2 sets of 750 patients each were randomly selected from these cases: Set 1 to develop hypotheses; Set 2 for validation. Tissue specimens were available from 643 (set1) and 679 (set2) cases (20% &amp; 22% total enrolled in 9344 respectively). HER2 was evaluated by FISH and by IHC (by antibody cb11 and by Herceptest). Statistical analyses used Cox proportional hazards models, including interaction terms, and Kaplan-Meier estimates for comparing 5-yr DFS by treatment group. Results: In Set 1, all 3 assays suggested that T improved DFS for HER2+ but not for HER2-. For this single set the interaction was not statistically significant. There appeared to be an interaction of HER2, T and ER. IHC using cb11 was applied to Set 2, revealing nearly identical results. In the two sets combined (n=1322), the interaction between HER2 and T was statistically significant (p=0.013). The 3-way interaction of HER2, ER and T was hypothesis-generating and not tested statistically. Differences in 5-yr DFS rates (95% CI) for T vs. no T by HER2 and ER (both sets combined) There was no interaction between HER2 and dose of A. Conclusions: These results suggest that the benefit of adding T to AC is greater for HER2+ tumors, even if ER+, while T was of no apparent benefit in the ER+, HER2- group. Further validation is needed from remaining cases in 9344 and from other trials involving T. [Table: see text] [Table: see text]
Mononucleosis?—Lymphoma? Mimicry of Infectious Mononucleosis and Malignant Lymphoma
Authors: S J WILSON, F A MANTZ, H R JACKSON
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial
Authors: Torsak Bunupuradah, Sasisopin Kiertiburanakul, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Malee Techapornroong, Niramon Leerattanapetch, Pacharee Kantipong, Chureeratana Bowonwatanuwong, Sukit Banchongkit, Virat Klinbuayaem, Sripetcharat Mekviwattanawong, Sireethorn Nimitvilai, Supunnee Jirajariyavej, Wisit Prasithsirikul, Warangkana Munsakul, Sorakij Bhakeecheep, Suchada Chaivooth, Praphan Phanuphak, David A Cooper, Tanakorn Apornpong, Stephen J Kerr, Sean Emery, Kiat Ruxrungtham
Journal: The Lancet HIV (2016)
An alternative approach to intragastric balloon retrieval
Authors: Galvao Neto, Josemberg Campos, Alvaro Ferraz, Ricardo Dib, Flavio Ferreira, Rena Moon, Andre Teixeira
Journal: Endoscopy (2016)

Placement of an intragastric balloon is a nonsurgical treatment for weight loss [1] [2]. Balloon retrieval can be difficult, however: forcing or persisting can cause perforation or esophageal laceration, as well as extending the anesthesia time [3] [4] [5].
Developing minimal national standards for clinical experience in psychiatric training
Authors: J Yager, J F Borus, C B Robinowitz, J H Shore
Journal: American Journal of Psychiatry (1988)

There are no minimum standards for the clinical training of psychiatrists with regard to the type and number of patients evaluated or treated. Interest in establishing such standards derives from a need for greater accountability, a high fail rate on the clinical portion of the American Board of Psychiatry and Neurology examinations, and an increasing demand for precise documentation of competence in specific areas by hospital privileging committees. Although considerable disagreement exists as to what the overall requirements should be, some minimum requirements can be agreed on. The authors discuss concerns about minimal standards and make suggestions for further development of standards.
Crack Cocaine Mimicking Pulmonary Embolism on Pulmonary Ventilation/Perfusion Lung Scan A Case Report
Authors: GARY T. SMITH, PATRICK L. McCLAUGHRY, JANET PURKEY, WARREN THOMPSON
Journal: Clinical Nuclear Medicine (1995)

Cocaine inhalation is associated with multiple pulmonary complications including pulmonary infiltrates, pulmonary edema, barotrauma, tracheal injury, and alveolar hemorrhage. Little has been reported about ventilation/perfusion (V/Q) lung scanning in patients who smoke cocaine. The authors report a case of inhalation cocaine abuse mimicking pulmonary embolism by V/Q scan criteria. This case report documenting perfusion abnormalities within hours of cocaine smoking which resolved within days provides the first in vivo evidence for pulmonary vasoconstriction.
Rate-sensitive inhibition of ACTH release in depression
Authors: D B Carr, C Wool, R B Lydiard, J Fisher, A Gelenberg, G Klerman
Journal: American Journal of Psychiatry (1984)

Rate-sensitive inhibition of ACTH release is abnormal in Cushing's disease but uncharacterized in depression. The authors found that two of 10 depressed patients had paradoxical responses, suggesting the existence of a hypothalamic-pituitary-adrenal axis abnormality in depression that is independent of dexamethasone suppression test results.
Abstract P1-10-23: Bladder symptoms in women with newly diagnosed breast cancer
Authors: L Wong, C Chung, S Flores, J Mortimer
Journal: Cancer Research (2016)

Abstract Background: Changes in bladder function are recognized effects of aging and menopause but have not generally been reported in women treated for breast cancer. We initiated a prospective trial to assess the impact of (neo) adjuvant therapy on women with early stage breast cancer. Methods: Women with newly diagnosed invasive breast cancer who were to initiate (neo) adjuvant chemotherapy or endocrine therapy were approached for study participation. At baseline a urinalysis, urine culture, and self assessment quality of life questionnaires were completed. The Urogenital Distress Inventory (UDI-6) assesses bladder symptoms and the Incontinence Impact Questionnaire (IIQ-7) assesses the impact of bladder symptoms on quality of life. Three months after initiation of (neo)adjuvant therapy, the quality of life questionnaires were repeated. We report the results of the pretreatment questionnaires. Results: Between February and June, 2015, forty-nine women with newly diagnosed breast cancer were enrolled on study. The median age was 54 (Range 25-78); 21 were premenopausal and 28 postmenopausal. Twenty nine (59%) were treated in the adjuvant setting; 12 with chemotherapy and 17 with endocrine therapy. Twenty patients, (41%) were treated in the neoadjuvant setting with chemotherapy. Prior to initiation of therapy, " Frequent urination" was reported in 38 (65%), " Leakage related to urgency" in 5 ( 10%), " Leakage with physical activity" in 32 (55%) and "Small amounts of leakage" in 32 (55%). Bladder symptoms impacted the ability to perform household chores in 8 (16%), Physical recreation in 10 (20%), social activities in 9 (18%), and Emotional health in 5 (10%). Conclusions: Symptoms of bladder dysfunction are common in women with newly diagnosed breast cancer even before therapy is initiated. Citation Format: Wong L, Chung C, Flores S, Mortimer J. Bladder symptoms in women with newly diagnosed breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-23.
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
Authors: Georg Schett, Paul Emery, Yoshiya Tanaka, Gerd Burmester, David S Pisetsky, Esperanza Naredo, Bruno Fautrel, Ronald van Vollenhoven
Journal: Annals of the Rheumatic Diseases (2016)

Improvements in the control of inflammation in rheumatoid arthritis (RA) by conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) have led to a substantial change in the clinical outcomes of patients during the last 30 years. Current treatment can lead to sustained remission in some patients raising questions about the optimal management strategies in this subgroup of patients. Today, tapering of DMARDs and even their discontinuation appears as an interesting concept for achieving a more tailored and dynamic treatment approach of RA, especially in patients, who achieved full disease control by DMARD treatment. In this review article, current developments of DMARD tapering are discussed. The article provides an overview of existing studies on this topic and addresses new strategies to reach drug-free remission. Furthermore, concepts for defining patients eligible for DMARD tapering are described and potential future strategies in using biomarkers in predicting the risk for disease relapse after initiation of DMARD tapering are addressed. These findings are finally considered in light of the vision to achieve cure as an ultimate goal in patients with RA achieving full control of inflammation.
ATPS-20AURORA KINASE B INHIBITOR AT9283 ENHANCED RADIATION THERAPY IN GLIOBLASTOMA
Authors: Jianwen Dong, Ravesanker Ezhilarasan, Shangfang Wu, Erik Sulman, John de Groot
Journal: Neuro-Oncology (2015)

High-grade gliomas are the most common type of primary brain tumor in adults. Of the three main therapies, surgical resection, radiation therapy and chemotherapy, radiation remains the most important and relatively efficacious therapy for primary brain tumors. However, most patients are refractory to radiation therapy, and this radioresistance ultimately leads to tumor recurrence. Aurora kinase A, B and C, are key regulators of mitosis and are over expressed in many of the human cancers. Given that radiosensitization may be enhanced for cells at the G2/M phase of the cell cycle, we attempted to increase radiosensitivity by treating cells with AT9283, a broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL. In this study, the in vitro therapeutic efficacy of AT9283 alone and in combination with radiation was investigated in a panel of gliomas stem cell (GSC) lines with specific molecular subtypes. Efficacy of AT9283 was analyzed by Cell-Titer Glo 5 days after treatment. Molecular and cellular changes were approached by immunoblotting and flow cytometry. AT9283 inhibited cell viability with an IC50 ranging from 0.078 µM to 3.15 µM, suppressed phosphorylation of histone H3 (Ser10) and phosphorylation of Aurora A/B/C in a dose- and time- dependent manner. AT-9283 is effective in inducing G2/M arrest and polyploidy cell formation, which is a consequence of mitotic defects. Treatment with AT9283 induced prominent cleaved poly ADP ribose polymerase (PARP), an index of apoptosis. AT9283 suppressed colony formation and this effect was enhanced by combination therapy with radiation. The promising in vitro results of AT9283 in GSCs led to further investigation of drug efficacy in an intracranial xenograft models comparing AT9283 alone, and in combination with radiation. In summary, this study demonstrates that AT9283 is a novel therapeutic approach for the treatment of glioblastoma alone and in combination with radiation.
Brief Communication: Immune Cytolysis of Rat Tumor Cells Mediated by Syngeneic “Immune” RNA2
Authors: David H. Kern, Carol R. Drogemuller, Yosef H. Pilch
Journal: JNCI Journal of the National Cancer Institute (1974)

Normal, nonimmune Fischer 344/N rat Iymphocytes were converted to effector cells, specifically cytotoxic to MC3-R tumor cells, by incubation in vitro with syngeneic “immune” RNA extracted either from the spleens of s)fngeneic Fischer 344/N rats bearing growing MC3-R tumor transplants or from the spleens of rats hyperimmunized with the MC3-R tumor. The degree of cytotoxicity obtained by this method was comparable in magnitude to the cytotoxicity of spleen cells from hyperimmunized rats. Spleen cells incubated with RNA from Fischer 344/N rats bearing a different tumor failed to lyse MC3-R tumor cells. These immune responses were abrogated when immune RNA was treated with RNAse before incubation with spleen cells, but treatment with DNAse or pronase d id not affect the activity of the immune RNA preparations. Concentrations of immune RNA as low as 100 µg/ml were effective in mediating these immune responses.
Q&amp;A: Ashok Venkitaraman on “Undruggable” Targets
Authors: Ashok Venkitaraman
Journal: Cancer Discovery (2013)

Abstract Ashok Venkitaraman, MD, PhD, professor of cancer research at the University of Cambridge in the UK, and director of the Medical Research Council's Cancer Cell Unit in Cambridge, discusses research to systematically extend the repertoire of druggable targets in cancer.
Plasma 10-hydroxynortriptyline and ECG changes in elderly depressed patients
Authors: R C Young, G S Alexopoulos, C A Shamoian, E Kent, A K Dhar, H Kutt
Journal: American Journal of Psychiatry (1985)

Among 18 elderly depressed patients given ECGs before and during nortriptyline treatment, plasma E-10-hydroxynortriptyline and the sum of E-10-hydroxynortriptyline and nortriptyline distinguished the group with conduction/repolarization effects. Plasma nortriptyline, age, drug dose, and baseline cardiovascular status did not.